Literature DB >> 17316146

Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.

Amy Barton Pai1, Alex V Boyd, Charles R McQuade, Antonia Harford, Jeffrey P Norenberg, Philip G Zager.   

Abstract

STUDY
OBJECTIVE: To compare non-transferrin-bound iron and markers of oxidative stress after single intravenous doses of iron dextran, sodium ferric gluconate, and iron sucrose.
DESIGN: Prospective, open-label, crossover study.
SETTING: University-affiliated general clinical research center. PATIENTS: Twelve ambulatory patients undergoing hemodialysis. INTERVENTION: Patients received 100 mg of intravenous iron dextran, sodium ferric gluconate, and iron sucrose in random sequence, with a 2-week washout period between treatments.
MEASUREMENTS AND MAIN RESULTS: Serum samples for transferrin saturation, non-transferrin-bound iron, and malondialdehyde (MDA; marker of lipid peroxidation) were obtained before (baseline) and 30, 60, 120, and 360 minutes and 2 weeks after each iron infusion. A serum sample for hemeoxygenase-1 (HO-1) RNA was obtained at baseline and 360 minutes after infusion. Non-transferrin-bound iron values were significantly higher 30 minutes after administration of sodium ferric gluconate and iron sucrose compared with iron dextran (mean +/- SEM 10.1 +/- 2.2, 3.8 +/- 0.8, and 0.23 +/-0.1 microM, respectively, p<0.001 for sodium ferric gluconate vs iron dextran, p = 0.002 for iron sucrose vs iron dextran). A significant positive correlation was noted between transferrin saturation and the presence of non-transferrin-bound iron for sodium ferric gluconate and iron sucrose (r2 = 0.37 and 0.45, respectively, p<0.001) but not for iron dextran (r2 = 0.09). After sodium ferric gluconate, significantly more samples showed increases in MDA levels from baseline compared with iron sucrose and iron dextran (p = 0.006); these increased levels were associated with the presence of non-transferrin-bound iron, baseline transferrin saturation above 30%, baseline transferrin levels below 180 mg/dl, and ferritin levels above 500 ng/ml (p<0.05). However, only a transferrin level below 180 mg/dl was independently associated (odds ratio 4.8, 95% confidence interval 1.2-15.3).
CONCLUSION: Iron sucrose and sodium ferric gluconate were associated with greater non-transferrin-bound iron appearance compared with iron dextran. However, only sodium ferric gluconate showed significant increases in lipid peroxidation. The relationship between non-transferrin-bound iron from intravenous iron and oxidative stress warrants further exploration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316146     DOI: 10.1592/phco.27.3.343

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  20 in total

1.  Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes.

Authors:  Hirohito Ichii; Yuichi Masuda; Tania Hassanzadeh; Mateen Saffarian; Sastry Gollapudi; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2012-06-19       Impact factor: 3.754

Review 2.  Considerations and challenges in defining optimal iron utilization in hemodialysis.

Authors:  David M Charytan; Amy Barton Pai; Christopher T Chan; Daniel W Coyne; Adriana M Hung; Csaba P Kovesdy; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 10.121

Review 3.  Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials.

Authors:  Nan Zheng; Dajun D Sun; Peng Zou; Wenlei Jiang
Journal:  AAPS J       Date:  2017-01-23       Impact factor: 4.009

Review 4.  The Labile Side of Iron Supplementation in CKD.

Authors:  Itzchak Slotki; Zvi Ioav Cabantchik
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

Review 5.  Iron and infection in hemodialysis patients.

Authors:  Julie H Ishida; Kirsten L Johansen
Journal:  Semin Dial       Date:  2013-12-12       Impact factor: 3.455

6.  Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival.

Authors:  Ajay Gupta; Jiaying Zhuo; Junli Zha; Srinivasa Reddy; Jonathan Olp; Amy Pai
Journal:  BMC Nephrol       Date:  2010-08-17       Impact factor: 2.388

7.  Outcomes Associated with Conventional Accelerated Versus Once-Weekly IV Iron Therapy in Outpatients Undergoing Hemodialysis.

Authors:  Marta Malkinska; Wasim S El Nekidy; Maher M El-Masri; Albert Kadri; Christine Donaldson; Derrick Soong
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

8.  Intravenous delivery of cysteamine for the treatment of cystinosis: association with hepatotoxicity.

Authors:  Michael R Bendel-Stenzel; Julia Steinke; Ranjan Dohil; Youngki Kim
Journal:  Pediatr Nephrol       Date:  2007-08-01       Impact factor: 3.714

Review 9.  Safety issues with intravenous iron products in the management of anemia in chronic kidney disease.

Authors:  Amir Hayat
Journal:  Clin Med Res       Date:  2008-12

10.  Brain edema in acute liver failure: inhibition by L-histidine.

Authors:  Kakulavarapu V Rama Rao; Pichili V B Reddy; Xiaoying Tong; Michael D Norenberg
Journal:  Am J Pathol       Date:  2010-01-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.